Our previously completed sustainability materiality assessment identified those we can impact: increasing access and affordability of medicines; meeting needs in emerging markets; furthering human rights; managing our supply chain; ecologically designing products; managing environmental impacts; meeting global health needs; ensuring quality and safety of products (including anticounterfeiting); supporting innovation, bioethics and responsible operation of clinical trials; and upholding business ethics and advancing health care compliance.